English to Russian Medical Medical (general)

Since publication of the 2017 Clinical Practice Guidelines for Clostridioides (formerly Clostridium) difficile infection (CDI), new relevant evidence has emerged for treatment options in the management of CDI in adults. The previous guidelines included pediatric treatment recommendations, but the scope of this focused update is restricted to adults and includes new data for fidaxomicin and for bezlotoxumab, a monoclonal antibody targeting toxin B produced by C. difficile. Both agents have increased clinical efficacy and other advantages over older agents, but implementation may be challenging because of initial monetary cost and logistics. In addition, the shift towards more sensitive diagnostic strategies emphasizes the importance of selecting appropriate patient populations and establishing the correct diagnosis when considering the use of these agents. While additional data have been published for other treatment entities, the quality of the data was determined not sufficient to alter our current treatment recommendations. New estimates on the burden of CDI have also been reported by the Centers for Disease Control and Prevention. While the adjusted estimate for total CDI burden nationally decreased by 24% from the previous report, they still estimated 462  100 cases annually and the burden of first CDI recurrences was unchanged. Recurrent CDI remains one of the most important treatment challenges for clinicians, with estimates of 31 300 and 38 500 recurrences for *community-associated* and healthcare-associated cases, respectively, in 2017.

(То есть, таких случаев меньше, чем healthcare-associated.)